---
name: 'microbiome-cancer-agent'
description: 'AI-powered analysis of microbiome-cancer interactions including tumor microbiome profiling, immunotherapy response prediction, and microbiome-targeted therapeutic opportunities.'
measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.
allowed-tools:
- read_file
- run_shell_command
---
# Microbiome-Cancer Interaction Agent
The **Microbiome-Cancer Interaction Agent** analyzes relationships between the microbiome and cancer, including tumor-associated bacteria, gut microbiome effects on immunotherapy, and microbiome-targeted therapeutic strategies.
## When to Use This Skill
* When analyzing tumor microbiome composition from sequencing data.
* To predict immunotherapy response based on gut microbiome profiles.
* For identifying microbiome-based biomarkers in cancer.
* When assessing antibiotic impact on cancer treatment efficacy.
* To design microbiome-modulating therapeutic interventions.
## Core Capabilities
1. **Tumor Microbiome Analysis**: Profile intratumoral bacteria from tumor sequencing data.
2. **Gut-Cancer Axis**: Analyze fecal microbiome associations with cancer outcomes.
3. **ICI Response Prediction**: Predict checkpoint inhibitor response from microbiome.
4. **Metabolite Profiling**: Link microbial metabolites to cancer phenotypes.
5. **Antibiotic Impact**: Model antibiotic effects on treatment efficacy.
6. **FMT/Probiotic Design**: Support microbiome-modulating interventions.
## Microbiome-Cancer Associations
| Cancer Type | Key Bacteria | Association |
|-------------|--------------|-------------|
| Colorectal | Fusobacterium nucleatum | Promotion, poor prognosis |
| Colorectal | Bacteroides fragilis (ETBF) | Carcinogenesis |
| Gastric | Helicobacter pylori | Established carcinogen |
| Pancreatic | Gammaproteobacteria | Drug metabolism |
| Breast | Fusobacterium | Metastasis |
| Oral | Porphyromonas gingivalis | Oral SCC |
## Workflow
1. **Input**: 16S/shotgun metagenomics, tumor sequencing, clinical data.
2. **Taxonomy Profiling**: Identify bacterial composition at genus/species level.
3. **Diversity Analysis**: Calculate alpha and beta diversity metrics.
4. **Association Testing**: Correlate microbiome with outcomes.
5. **Functional Prediction**: Infer metabolic potential (PICRUSt2, HUMAnN).
6. **Prediction Modeling**: Build response prediction models.
7. **Output**: Microbiome profile, associations, predictions, interventions.
## Example Usage
**User**: "Analyze gut microbiome from melanoma patients and predict anti-PD-1 response."
**Agent Action**:
```bash
python3 Skills/Microbiome/Microbiome_Cancer_Agent/microbiome_cancer.py \
--metagenomics fecal_shotgun.fastq.gz \
--tumor_data melanoma_rnaseq.tsv \
--clinical treatment_outcomes.csv \
--analysis ici_response \
--reference metaphlan_db \
--output microbiome_report/
```
## ICI Response and Microbiome
**Favorable Microbiome**:
- Akkermansia muciniphila
- Faecalibacterium prausnitzii
- Bifidobacterium spp.
- Ruminococcaceae family
- High diversity
**Unfavorable Microbiome**:
- Bacteroidales (in some studies)
- Low diversity
- Post-antibiotic dysbiosis
## Microbial Metabolites in Cancer
| Metabolite | Source | Effect |
|------------|--------|--------|
| Butyrate | Clostridia | Anti-inflammatory, anti-tumor |
| Inosine | Akkermansia | Enhanced ICI response |
| TMAO | Various | Pro-tumorigenic |
| Secondary bile acids | Various | Variable, context-dependent |
| LPS | Gram-negative | Inflammation, mixed effects |
## AI/ML Components
**Response Prediction**:
- Random forest on microbiome features
- Neural networks for metagenomic profiles
- Integration with host factors
**Microbiome-Metabolite Linking**:
- Genome-scale metabolic models
- Correlation networks
- Causal inference methods
**Intervention Design**:
- FMT donor selection
- Probiotic consortium optimization
- Antibiotic avoidance recommendations
## Tumor Microbiome Analysis
**Challenges**:
- Low bacterial biomass in tumors
- Contamination from reagents/environment
- Batch effects
- Need for stringent controls
**Best Practices**:
- Negative controls (extraction, PCR)
- Decontamination algorithms (decontam, SCRuB)
- Multiple validation methods
- Orthogonal confirmation (FISH, culture)
## Clinical Implications
1. **Biomarker Development**: Microbiome-based response prediction
2. **Intervention Timing**: Avoid antibiotics pre-ICI
3. **FMT Trials**: Responder microbiome transfer
4. **Probiotics**: Rationally designed consortia
5. **Prebiotics**: Fiber to support beneficial bacteria
## Prerequisites
* Python 3.10+
* QIIME2, Metaphlan, HUMAnN
* R (phyloseq, vegan)
* ML frameworks
## Related Skills
* Metagenomics - For general microbiome analysis
* Immune_Checkpoint_Combination_Agent - For ICI optimization
* Metabolomics - For metabolite analysis
## Research Frontiers
1. **Intratumoral bacteria**: Direct tumor effects
2. **Phage therapy**: Targeting pathobionts
3. **Engineered probiotics**: Drug-producing bacteria
4. **Diet interventions**: Modulating microbiome for therapy